Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Chest
|
October 1, 1983
Additive pulmonary toxicity with melphalan and busulfan therapy
D Schallier, N Impens, F Warson, et al.
Anticancer Research
|
March 1, 1995
Combination chemotherapy with carboplatin, cyclophosphamide and fluorouracil in advanced breast cancer
M T Closon, L Verbeke, J P Kains, et al.
Cancer Treatment Reports
|
May 1, 1984
Good response of a paraneoplastic neuromyopathy to cyclophosphamide
M Bruyland, S Van Belle, D Schallier, et al.
European Neurology
|
January 1, 1986
Periventricular metastases of a primary intracranial alpha-fetoprotein-producing germ cell tumor
M Bruyland, O Peters, D Schallier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2014
Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients
C Collen, N Christian, D Schallier, et al.
Journal of Immunology Research
|
June 2, 2018
The Relationship between a New Biomarker of Vagal Neuroimmunomodulation and Survival in Two Fatal Cancers
Y Gidron, M De Couck, D Schallier, et al.
Anticancer Research
|
June 9, 2001
Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC)
P Glorieux, P Ortmanns, S Marien, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 6, 2007
A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC)
D Schallier, B Neyns, C Fontaine, et al.
Medical Oncology and Tumor Pharmacotherapy
|
January 1, 1990
Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC)
P Weynants, Y Humblet, A Bosly, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 9, 2008
Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)
L Decoster, D Schallier, H Everaert, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Chest
|
October 1, 1983
Additive pulmonary toxicity with melphalan and busulfan therapy
D Schallier, N Impens, F Warson, et al.
Anticancer Research
|
March 1, 1995
Combination chemotherapy with carboplatin, cyclophosphamide and fluorouracil in advanced breast cancer
M T Closon, L Verbeke, J P Kains, et al.
Cancer Treatment Reports
|
May 1, 1984
Good response of a paraneoplastic neuromyopathy to cyclophosphamide
M Bruyland, S Van Belle, D Schallier, et al.
European Neurology
|
January 1, 1986
Periventricular metastases of a primary intracranial alpha-fetoprotein-producing germ cell tumor
M Bruyland, O Peters, D Schallier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 13, 2014
Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients
C Collen, N Christian, D Schallier, et al.
Journal of Immunology Research
|
June 2, 2018
The Relationship between a New Biomarker of Vagal Neuroimmunomodulation and Survival in Two Fatal Cancers
Y Gidron, M De Couck, D Schallier, et al.
Anticancer Research
|
June 9, 2001
Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC)
P Glorieux, P Ortmanns, S Marien, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 6, 2007
A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC)
D Schallier, B Neyns, C Fontaine, et al.
Medical Oncology and Tumor Pharmacotherapy
|
January 1, 1990
Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC)
P Weynants, Y Humblet, A Bosly, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 9, 2008
Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC)
L Decoster, D Schallier, H Everaert, et al.
Page
of 3